Literature DB >> 19902472

Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Kazutoshi Fujita1, Charles M Ewing, Robert H Getzenberg, J Kellogg Parsons, William B Isaacs, Christian P Pavlovich.   

Abstract

BACKGROUND: Chronic inflammation is commonly observed in benign prostate hyperplasia (BPH), and prostate tissue often contains increased inflammatory infiltrates, including T cells and macrophages. Cytokines are not only key mediators of inflammation but may also play important roles in the initiation and progression of BPH.
METHODS: In order to determine what cytokines might be involved in prostatic enlargement, expressed prostatic secretions (EPS) from ex vivo prostates were analyzed by human cytokine antibody microarray and ELISA. Prostate epithelial cells (PrEC) and prostate stromal cells (PrSC) were used for ELISA, proliferation, and Western blot assays.
RESULTS: Monocyte chemotactic protein-1 (MCP-1/CCL2) was one of the most elevated proteins in secretions from large prostate glands. PrSC were found to secrete MCP-1; Western blotting showed that both PrSC and PrEC express the MCP-1 receptor CCR2 which by RT-PCR was the CCR2b isoform. Proliferation assays showed that MCP-1 stimulates the proliferation of PrEC, but not PrSC, and that a specific MCP-1 antagonist (RS102895) suppressed this effect. Conditioned medium from PrSC stimulated the proliferation of PrEC as well, an effect completely inhibited by both RS102895 and a neutralizing anti-MCP-1 monoclonal antibody. The inflammatory cytokines interleukin (IL)-1 beta, interferon-gamma, and IL-2 enhanced the secretion of MCP-1 from PrEC and PrSC. In addition, MCP-1 levels in EPS correlated with mRNA levels of the macrophage marker CD68 in the same secretions.
CONCLUSIONS: The cytokine MCP-1, of apparent prostatic stromal cell origin, may play an important role in prostatic enlargement and BPH, and is a candidate biomarker for these pathologic processes. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19902472      PMCID: PMC4789093          DOI: 10.1002/pros.21081

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  32 in total

1.  Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.

Authors:  G Theyer; G Kramer; I Assmann; E Sherwood; W Preinfalk; M Marberger; O Zechner; G E Steiner
Journal:  Lab Invest       Date:  1992-01       Impact factor: 5.662

2.  Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.

Authors:  Gero Kramer; Georg E Steiner; Alessandra Handisurya; Ursula Stix; Andrea Haitel; Birgit Knerer; Alois Gessl; Chung Lee; Michael Marberger
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

3.  Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.

Authors:  Yi Lu; Zhong Cai; Deborah L Galson; Guozhi Xiao; Yulin Liu; Diane E George; Mona F Melhem; Zhi Yao; Jian Zhang
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

4.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

Authors:  Robert D Loberg; LaShon L Day; Jason Harwood; Chi Ying; Lauren N St John; Ryan Giles; Chris K Neeley; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

5.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

Review 7.  Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies.

Authors:  Christine Daly; Barrett J Rollins
Journal:  Microcirculation       Date:  2003-06       Impact factor: 2.628

8.  Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation.

Authors:  Kazutoshi Fujita; Charles M Ewing; Lori J Sokoll; Debra J Elliott; Mark Cunningham; Angelo M De Marzo; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

9.  Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.

Authors:  Georg E Steiner; Ursula Stix; Alessandra Handisurya; Martin Willheim; Andrea Haitel; Franz Reithmayr; Doris Paikl; Rupert C Ecker; Kristian Hrachowitz; Gero Kramer; Chung Lee; Michael Marberger
Journal:  Lab Invest       Date:  2003-08       Impact factor: 5.662

10.  Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes.

Authors:  D D Taub; P Proost; W J Murphy; M Anver; D L Longo; J van Damme; J J Oppenheim
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  25 in total

1.  Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators.

Authors:  Praveen Thumbikat; Shiva Shahrara; Rudina Sobkoviak; Joseph Done; Richard M Pope; Anthony J Schaeffer
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

2.  Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.

Authors:  Pradeep Tyagi; Saundra S Motley; Tatsuki Koyama; Mahendra Kashyap; Jeffrey Gingrich; Naoki Yoshimura; Jay H Fowke
Journal:  Prostate       Date:  2017-10-27       Impact factor: 4.104

Review 3.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

4.  Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

Authors:  Michael K Brawer; Stacy Loeb; Alan W Partin; Naoki Yoshimura; Michael B Chancellor; Claus G Roehrborn; Dean G Assimos; J Curtis Nickel; B Shuch; F Pouliot; Arie S Belldegrun; Ellen Shapiro
Journal:  Rev Urol       Date:  2009

5.  Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.

Authors:  Yasuhito Funahashi; Katherine J O'Malley; Naoki Kawamorita; Pradeep Tyagi; Donald B DeFranco; Ryosuke Takahashi; Momokazu Gotoh; Zhou Wang; Naoki Yoshimura
Journal:  Prostate       Date:  2013-12-17       Impact factor: 4.104

6.  Urine chemokines indicate pathogenic association of obesity with BPH/LUTS.

Authors:  Pradeep Tyagi; Saundra S Motley; Mahendra Kashyap; Subrata Pore; Jeffrey Gingrich; Zhou Wang; Naoki Yoshimura; Jay H Fowke
Journal:  Int Urol Nephrol       Date:  2015-04-30       Impact factor: 2.370

Review 7.  Chemokines and BPH/LUTS.

Authors:  Jill A Macoska
Journal:  Differentiation       Date:  2011-05-19       Impact factor: 3.880

Review 8.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

9.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

Review 10.  Inflammatory mediators in the development and progression of benign prostatic hyperplasia.

Authors:  Cosimo De Nunzio; Fabrizio Presicce; Andrea Tubaro
Journal:  Nat Rev Urol       Date:  2016-09-30       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.